PTGX — Protagonist Therapeutics, Inc. stock price, charts and financials
QT68Protagonist Therapeutics, Inc.Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
143.70
+0.86+0.60%
News
Up 0.6% — Protagonist Therapeutics (NASDAQ:PTGX) Combines High Growth Momentum With a Breakout Setup (ChartMill).
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | 139.51 | EPS (ttm) | 1.03 | Insider Own | 6.89% | Shs Outstand | 64.31M | Perf Week | -1.01% |
| Market Cap | 9.24B | Forward P/E | - | EPS next Y | -0.49 | Insider Trans | -11.43% | Shs Float | 52.49M | Perf Month | -8.67% |
| Enterprise Value | 8.47B | PEG | 11.95 | EPS next Q | 2.43 | Inst Own | - | Short Float | 14.69% | Perf Quarter | 28.95% |
| Income | 84.00M | P/S | 32.89 | EPS this Y | 353.42% | Inst Trans | - | Short Ratio | 11.28 | Perf Half Y | 48.01% |
| Sales | 281.00M | P/B | 10.98 | EPS next Y | -110.51% | ROA | 9.36% | Short Interest | 7.71M | Perf YTD | 64.53% |
| Book/sh | 13.09 | P/C | 11.80 | EPS next 5Y | 11.67% | ROE | 12.03% | 52W High | 160.81 -10.64% | Perf Year | 145.26% |
| Cash/sh | 12.18 | P/FCF | 72.10 | EPS past 3/5Y | - | ROIC | 6.74% | 52W Low | 58.91 143.93% | Perf 3Y | 663.96% |
| Dividend Est. | - | EV/EBITDA | 98.46 | Sales past 3/5Y | 19.43% 9.67% | Gross Margin | 99.86% | Volatility | 3.38% 3.73% | Perf 5Y | 213.62% |
| Dividend TTM | - | EV/Sales | 30.13 | EPS Y/Y TTM | -75.65% | Oper. Margin | 20.69% | ATR (14) | 5.46 | Perf 10Y | 1037.77% |
| Dividend Ex-Date | - | Quick Ratio | 21.71 | Sales Y/Y TTM | -35.25% | Profit Margin | 29.40% | RSI (14) | 46.34 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 21.71 | EPS Q/Q | 516.36% | SMA20 | -2.66% | Beta | 1.47 | Target Price | 169.38 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | 3450.00% | SMA50 | 0.12% | Rel Volume | 0.84 | Prev Close | 142.84 |
| Employees | 141 | LT Debt/Eq | 0.01 | Earnings | Nov 05 | SMA200 | 32.58% | Avg Volume | 662.32K | Price | 143.70 |
| IPO Date | Aug 11, 2016 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2.56% 5.32% | Net Debt/EBITDA | -4.81 | Volume | 558,897 | Change | 0.60% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-01-26 | Reiterated | Barclays | Overweight | $153 → $180 |
| Sep-01-26 | Reiterated | BMO Capital | Outperform | $178 → $190 |
| Aug-31-26 | Reiterated | HC Wainwright & Co. | Buy | $117 → $170 |
| Aug-17-26 | Reiterated | BMO Capital | Outperform | $62 → $178 |
| Aug-10-26 | Upgrade | Goldman Sachs | Neutral → Buy | $110 → $186 |
| Aug-10-26 | Reiterated | Truist Securities | Buy | $145 → $170 |
| Aug-10-26 | Reiterated | Wedbush | Outperform | $70 → $173 |
| Aug-06-26 | Reiterated | Barclays | Overweight | $151 → $153 |
| Jul-17-26 | Reiterated | Johnson Rice | $137 → $165 | |
| Jul-14-26 | Reiterated | Barclays | Overweight | $108 → $151 |
Latest News· Times ET
Sep-15-26
Sep-15-2606:41AM
Sep-13-26
Sep-13-2612:43AM
12:10AM
Sep-11-26
Sep-11-2612:12AM
Sep-09-26
Sep-09-2611:27AM
Sep-08-26
Sep-08-2612:05PM
Protagonist Therapeutics Announces $300 Million Share Repurchase Programaccessnewswire.com
Sep-06-26
Sep-02-26
Sep-02-2603:05AM
Sep-01-26
Sep-01-2610:44AM
Aug-31-26
Aug-31-2611:54AM
10:02AM
Aug-28-26
Aug-28-2604:30PM
05:01AM
Aug-27-26
Aug-27-2611:53PM
Company
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 281 | 46 | 434 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 1 | 0 | — | — | — | — | — | — | |
| Gross Profit | 281 | 45 | 434 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 48 | 45 | 43 | — | — | — | — | — | — | |
| Research and Development | 175 | 159 | 138 | — | — | — | — | — | — | |
| Other Operating Expense | 1 | -1 | 1 | — | — | — | — | — | — | |
| Operating Income | 59 | -158 | 253 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 26 | 29 | 27 | — | — | — | — | — | — | |
| Net Income Before Taxes | 84 | -129 | 279 | — | — | — | — | — | — | |
| Income Taxes | 1 | 1 | 4 | — | — | — | — | — | — | |
| Consolidated Net Income | 84 | -130 | 275 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 84 | -130 | 275 | — | — | — | — | — | — | |
| Net Income | 84 | -130 | 275 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.22 | -2.05 | 4.47 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.22 | -2.05 | 4.47 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.03 | -2.05 | 4.23 | — | — | — | — | — | — | |
| EBITDA | 86 | -128 | 280 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 139.51 | — | 9.13 | — | — | — | — | — | — | |
| Price To Sales Ratio | 33.75 | 121.52 | 5.51 | — | — | — | — | — | — | |
| Gross Margin | 100.00 | 97.83 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | 21.00 | -343.48 | 58.29 | — | — | — | — | — | — | |
| Net Margin | 29.89 | -282.61 | 63.36 | — | — | — | — | — | — | |
| Shares Outstanding | 66 | 64 | 62 | — | — | — | — | — | — | |
| Market Capitalization | 9,484 | 5,590 | 2,393 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| PATEL DINESH V PH D | President and CEO | Sep 10 '26 | Option Exercise | 21.58 | 7,278 | 157,059 | 530,246 | Sep 10 |
| PATEL DINESH V PH D | President and CEO | Sep 10 '26 | Sale | 144.10 | 7,278 | 1,048,760 | 522,968 | Sep 10 |
| PATEL DINESH V PH D | President and CEO | Sep 09 '26 | Option Exercise | 21.58 | 63,548 | 1,371,366 | 586,516 | Sep 10 |
| PATEL DINESH V PH D | President and CEO | Sep 09 '26 | Sale | 146.18 | 63,548 | 9,289,447 | 522,968 | Sep 10 |
| PATEL DINESH V PH D | President and CEO | Sep 08 '26 | Sale | 145.87 | 54,174 | 7,902,361 | 522,968 | Sep 10 |
| PATEL DINESH V PH D | President and CEO | Sep 08 '26 | Option Exercise | 21.58 | 54,174 | 1,169,075 | 577,142 | Sep 10 |
| PATEL DINESH V PH D | President and CEO | Aug 11 '26 | Option Exercise | 21.58 | 34,239 | 738,878 | 557,717 | Aug 12 |
| PATEL DINESH V PH D | President and CEO | Aug 11 '26 | Sale | 148.52 | 34,239 | 5,085,176 | 523,478 | Aug 12 |
| PATEL DINESH V PH D | President and CEO | Aug 10 '26 | Option Exercise | 21.58 | 65,761 | 1,419,122 | 589,239 | Aug 12 |
| PATEL DINESH V PH D | President and CEO | Aug 10 '26 | Sale | 149.11 | 65,761 | 9,805,623 | 523,478 | Aug 12 |
| Waddill William D. | Director | Jun 23 '26 | Option Exercise | 16.54 | 9,000 | 148,860 | 16,825 | Jun 25 |
| Waddill William D. | Director | Jun 23 '26 | Sale | 117.94 | 9,000 | 1,061,460 | 7,825 | Jun 25 |
| Waddill William D. | Director | Jun 10 '26 | Option Exercise | 14.96 | 9,000 | 134,640 | 16,825 | Jun 11 |
| Waddill William D. | Director | Jun 10 '26 | Sale | 107.68 | 9,000 | 969,120 | 7,825 | Jun 11 |
| Waddill William D. | Director | May 29 '26 | Option Exercise | 11.80 | 9,000 | 106,200 | 16,825 | Jun 01 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.